Safe, pure, sustainable ingredients for life
Why Willow
We believe in challenging conventional methods to bring the benefits of nature to everyone. Your customers and your industry demand the safest, most pure active pharmaceutical ingredients (APIs) available. Few can deliver. We can. Beginning with Cannabigerol (CBG) and other cannabinoids, our leading biotechnology platform allows us to deliver consistent, economical, sustainable ingredients at a global scale.
04 Purification
Our production technology produces cannabinoids that are identical to cannabinoids produced in plants, but free of the pesticides, waxes, and heavy metals often found in plant feedstocks. It also produces only one type of cannabinoid at a time, making purification far easier.
01 Plant Biotech
Nature’s instructions for producing cannabinoids are encoded in the cannabis plant’s genome. We follow nature’s lead by identifying the genes responsible for cannabinoid production in cannabis.
02 Biosynthesis
We transfer that genetic information into yeast, transforming the yeast host into an extraordinary miniature cannabinoid factory. The process is economical and meticulously monitored to ensure quality.
03 Yeast Fermentation
Combining low-cost inputs with our optimized yeast strains in a fermentation vessel results in an ideal manufacturing platform. Unlike plant-based production which can take months, our process takes just days.
04 Purification
Our production technology produces cannabinoids that are identical to cannabinoids produced in plants, but free of the pesticides, waxes, and heavy metals often found in plant feedstocks. It also produces only one type of cannabinoid at a time, making purification far easier.
01 Plant Biotech
Nature’s instructions for producing cannabinoids are encoded in the cannabis plant’s genome. We follow nature’s lead by identifying the genes responsible for cannabinoid production in cannabis.
02 Biosynthesis
We transfer that genetic information into yeast, transforming the yeast host into an extraordinary miniature cannabinoid factory. The process is economical and meticulously monitored to ensure quality.
03 Yeast Fermentation
Combining low-cost inputs with our optimized yeast strains in a fermentation vessel results in an ideal manufacturing platform. Unlike plant-based production which can take months, our process takes just days.
04 Purification
Our production technology produces cannabinoids that are identical to cannabinoids produced in plants, but free of the pesticides, waxes, and heavy metals often found in plant feedstocks. It also produces only one type of cannabinoid at a time, making purification far easier.
Our Platform
Higher purity, lower cost
Plants are the best scientists. Using the instructions contained in the genes of therapeutic plants, we can produce the same compounds at higher purity, speed, consistency, and cost-effectiveness, but smaller environmental impact than traditional agriculture practices.
Our innovative research platform reinvents the production of active pharmaceutical ingredient (API) supplies for global pharmaceutical, health and wellness, and consumer packaged goods industries. Our current focus is on the production of pure CBG, with plans to target many more plant-sourced drugs in the future.
Reliable capacity
We are building to meet big needs – and small too. From grams to metric tons, our platform and partnerships will provide the ability to scale production to meet the needs of the smallest to the largest pharmaceutical and consumer packaged goods clients.
Simplified supply chain
The supply chain for our platform technology that produces CBG is far simpler than plant-based cannabinoids. Our partner Albany Molecular Research, Inc.’s (AMRI) infrastructure is already in place to meet the demand of clients across the globe.
Production looming
Though our platform is in place, there remain several steps to bring bio-synthetic cannabinoids to market. We expect to be in production of pure CBG isolate in late 2021/early 2022. If you have questions, please contact us for more information.
Trusted team
With extensive experience in industrial biotechnology and an impressive background in launching successful businesses, our team possesses all the tools needed for success.
Industry awarded
Our 35 person science and technical tram has a collective 21 PhDs among them and our business team is responsible for cofounding five companies in senior executive roles, which in total sold for over $4 billion.
Products
CBG
Cannabigerol (CBG) is yet to match the mainstream appeal of CBD, but will soon play a significant role in everyday consumer life as it demonstrates a wide array of intriguing medicinal benefits. This bioactive ingredient activates both CB1 and CB2 cannabinoids receptors and has already received significant interest by discriminating formulators who appreciate that it exhibits anti-bacterial, anti-microbial, and anti-inflammatory properties. A summary of recent research with this cannabinoid has been involved with the following areas:
This is a summary of research interest(s) for each cannabinoid being discussed. These statements have not been evaluated by the USA Food and Drug Administration, nor any regional regulatory body. This ingredient is not intended to diagnose, treat, cure, or prevent any disease.
CBD
Cannabidiol (CBD) is the posterchild of the cannabinoid industry and earns its reputation by binding to CB2 cannabinoid receptors within our bodies’ endocannabinoid system. This effects our peripheral nervous system to help regulate various physiological functions with muscles, immune cells, skin, and other organs. A summary of recent research with this cannabinoid has been involved with the following areas:
This is a summary of research interest(s) for each cannabinoid being discussed. These statements have not been evaluated by the USA Food and Drug Administration, nor any regional regulatory body. This ingredient is not intended to diagnose, treat, cure, or prevent any disease.
CBGV
Cannabigerivarin (CBGV) is theorized to boost the ability of the CB2 receptors within the endocannabinoid system and those found in our immune system, as well as impact how other cannabinoids molecules are activated and metabolized within the body, especially as it relates to pain and inflammation. A summary of recent research with this cannabinoid has been involved with the following areas:
This is a summary of research interest(s) for each cannabinoid being discussed. These statements have not been evaluated by the USA Food and Drug Administration, nor any regional regulatory body. This ingredient is not intended to diagnose, treat, cure, or prevent any disease.
THCV
Tetrahydrocannabivarin (THCV) is similar to THC in chemical structure, exerts similar psychoactive effects on the body at higher level of intake, yet unlike THC actually mitigates this effect at lower levels of intake. These opposing impacts based upon concentration and dosage may be explained by it acting as both an agonist and an antagonist at CB1 receptors, with additional peripheral tissue effects related to neurogenesis and satiety. A summary of recent research with this cannabinoid has been involved with the following areas:
This is a summary of research interest(s) for each cannabinoid being discussed. These statements have not been evaluated by the USA Food and Drug Administration, nor any regional regulatory body. This ingredient is not intended to diagnose, treat, cure, or prevent any disease.
CBDV
Cannabidivarin (CBDV) like its parent compound CBD, is well positioned through active pharmaceutical ingredient research as a potentially powerful cannabinoid related to epileptic seizures. It acts at both CB1 and CB2 cannabinoid receptors and also effects how endogenous cannabinoids are synthesized within the endocannabinoid system. A summary of recent research with this cannabinoid has been involved with the following areas:
This is a summary of research interest(s) for each cannabinoid being discussed. These statements have not been evaluated by the USA Food and Drug Administration, nor any regional regulatory body. This ingredient is not intended to diagnose, treat, cure, or prevent any disease.
About Us
Not everyone can do what we do. We are an elite team of scientists and business leaders pioneering how synthetic biology can bring the best of nature’s ingredients to market.
Management Team
Trevor Peters
President and Chief Executive Officer and Director
Mr. Peters is an experienced executive having co-founded four start-up companies in the past 15 years. Mr. Peters has raised over $1.0 billion in...
Travis Doupe
Chief Financial Officer
Mr. Doupe has over 18 years' experience in financial leadership roles, principally in the international oil and gas industry, during which time he...
Dr. Chris Savile
Chief Operations Officer
Dr. Savile has 13 years’ experience in science, business development, and commercial operations roles in biotech. He is a highly experienced chemist,...
Simon Hickling, PhD
SVP Business Development
25 years’ experience in production and international business development in the pharmaceutical and biotech industry, having previously held roles at...
Dr. Trish Choudhary
Vice President, Research & Development
Dr. Choudhary has 15 years' experience in R&D and lab operations optimizing biological processes for industrial biotech and food applications. She is...
Board of Directors
Dr. Peter Seufer-Wasserthal
Chairman
Dr. Seufer-Wasserthal has more than 25 years’ experience in the technology and biotechnology sector. Dr. Seufer-Wasserthal is currently Chief...
Barbara Munroe
Independent Director
More than 25 years of experience as a lawyer and executive in diverse industries. Current Chair of the Board of Crescent Point Energy Corp. Has served...
Al Foreman
Independent Director
Mr. Foreman has over 20 years of professional experience in private equity, corporate finance, and financial technology. Mr. Foreman is currently a...
Sadiq H. Lalani
Independent Director
Mr. Lalani has been Chief Financial Officer of Kelt Exploration Ltd. since October 2012 and Vice President since October 2017. Before that, Mr. Lalani...
Donald Archibald
Independent Director
Mr. Archibald is an independent businessman and the Executive Chairman of Cequence Energy Ltd. and a director of Spartan Delta Corp. Mr. Archibald was...
Strategically located facilities
We currently have facilities with over thirty science and technical staff in close proximity to allied university research and biotechnology hubs.
Please direct inquiries to our head office in Calgary, AB
Phone +1 403-910-5140
Email info@willowbio.com
Vancouver, BC
Focused on understanding the process of cannabinoid biosynthesis in cannabis plants for translation into yeast-based biosynthesis platforms. This facility houses state-of-the-art molecular biology and analytical chemistry capabilities, in addition to automated workflows supporting yeast strain engineering.Mountain View, CA
Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our cannabinoid-producing yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.Strategically located facilities
Vancouver, BC
Focused on understanding the process of cannabinoid biosynthesis in cannabis plants for translation into yeast-based biosynthesis platforms. This facility houses state-of-the-art molecular biology and analytical chemistry capabilities, in addition to automated workflows supporting yeast strain engineering.Mountain View, CA
Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our cannabinoid-producing yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.We currently have facilities with over thirty science and technical staff in close proximity to allied university research and biotechnology hubs.
Please direct inquiries to our head office in Calgary, AB
Email info@willowbio.com
Careers
We are game-changers and rule breakers. We shake things up, we discover, we create, we push boundaries and we deliver, always.
Investors
Based in Vancouver, British Columbia, Willow Biosciences is a biotechnology company focused on revolutionizing industrial manufacturing of active pharmaceutical ingredients and other high value products that have traditionally been derived from plants.
Current WLLW stock price
data currently unavailable
Press releases
12/05/2022
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2022 RESULTS
Vancouver, British Columbia – May 12, 2022 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF), a leading biotechnology…
News
12/05/2022
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2022 RESULTS
Vancouver, British Columbia – May 12, 2022 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF), a leading biotechnology…
31/01/2022
WILLOW BIOSCIENCES TO HOST INVESTOR PRESENTATION WEBCAST
Vancouver, British Columbia – January 31, 2022 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF), a leading…
15/11/2021
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2021 RESULTS
Vancouver, British Columbia – November 15, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) has released its…
09/08/2021
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2021 RESULTS
Vancouver, British Columbia – August 9, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) has released its…
10/06/2021
WILLOW BIOSCIENCES AND CELLULAR GOODS ANNOUNCE MULTIYEAR SUPPLY AGREEMENT FOR CANNABIGEROL (CBG)
Vancouver, British Columbia – June 10, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF), a biotechnology company…
25/05/2021
WILLOW BIOSCIENCES ANNOUNCES PARTICIPATION IN SYNBIOBETA PANEL DISCUSSION
Vancouver, British Columbia – May 25, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF), a Canadian biotechnology…
18/05/2021
WILLOW BIOSCIENCES ADDED TO NYSE-LISTED CANNABIS ETF "THCX"
Vancouver, British Columbia – May 18, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF), a Canadian biotechnology…
28/04/2021
WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
Vancouver, British Columbia – April 28, 2021 – Willow Biosciences Inc. ("Willow" or "the Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce…
20/04/2021
WILLOW BIOSCIENCES ANNOUNCES GROUND-BREAKING SCIENTIFIC DATA FOR CANNABIGEROL (CBG) ON HUMAN SKIN
Vancouver, British Columbia – April 20, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce…
31/03/2021
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF ITS FIRST COMMERCIAL SCALE FERMENTATION RUN
Vancouver, British Columbia – March 31, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce…
24/03/2021
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND 2020 YEAR END RESULTS AND OPERATIONAL UPDATE
Calgary, Alberta – March 23, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce its financial…
11/02/2021
WILLOW BIOSCIENCES ANNOUNCES INCREASE TO BOUGHT DEAL OFFERING FROM $20.0 MILLION TO $25.0 MILLION
Vancouver, British Columbia – Feb. 11, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; WLLW.WT; OTCQX: CANSF) is pleased to…
19/01/2021
WILLOW BIOSCIENCES ADVANCES ITS WORK ON THC; PLANS TO LAUNCH IN THE CANADIAN MARKET
Vancouver, British Columbia – January 19, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce…
13/01/2021
WILLOW BIOSCIENCES PROVIDES UPDATE ON CANNABIGEROL RESEARCH STUDIES AND KEY PERSONNEL APPOINTMENT
Vancouver, British Columbia – January 13, 2021 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce…
13/11/2020
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2020 RESULTS AND OPERATIONAL UPDATE
Calgary, Alberta – November 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) has released its financial and…
21/09/2020
WILLOW BIOSCIENCES ANNOUNCES SUCCESSFUL PRODUCTION OF PURE CANNABIGEROL
Vancouver, British Columbia – Sept 21, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce…
08/09/2020
WILLOW BIOSCIENCES ANNOUNCES RESEARCH AND DEVELOPMENT FUNDING FOR ITS VARIN CANNABINOIDS
Vancouver, British Columbia – September 8, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce…
12/08/2020
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2020 RESULTS AND OPERATIONAL UPDATE
Calgary, Alberta – August 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) has released its financial and…
29/07/2020
WILLOW BIOSCIENCES ANNOUNCES IT HAS COMMENCED ITS PILOT TO PRODUCE ITS FIRST CANNABINOID
Vancouver, British Columbia – July 29, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQX: CANSF) is pleased to announce…
06/07/2020
Willow Biosciences Inc. to Webcast Live at VirtualInvestorConferences.com July 9th
VANCOUVER, BC, July 6, 2020 /PRNewswire/ -- Willow Biosciences Inc. (TSX: WLLW,OTCQB: CANSF), based in Vancouver, Canada, focused on manufacturing…
22/06/2020
WILLOW BIOSCIENCES ANNOUNCES APPOINTMENT OF SENIOR VICE PRESIDENT, SALES AND MARKETING
Calgary, Alberta – June 22, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) is pleased to announce that…
14/05/2020
Willow Biosciences Reports First Quarter 2020 Results and Provides Operations Update
Calgary, Alberta – May 14, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) has released its financial and…
09/04/2020
Willow Biosciences Announces Changes To Its Management Team
Calgary, Alberta – April 7, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) announces changes to its management…
24/03/2020
Willow Biosciences Reports Fourth Quarter And 2019 Year End Results And Operational Update
Calgary, Alberta – March 24, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF), is pleased to announce its…
12/03/2020
Willow Biosciences Announces Cannabinoid Scale-up And Expedited Path To Commercialization
Calgary, Alberta – March 12, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF), is pleased to announce that it has…
07/02/2020
Willow Biosciences Improves Governance With Appointment Of Independent Chairman
Calgary, Alberta – February 7, 2020 – Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW; OTCQB: CANSF) is pleased to announce that it has…
03/12/2019
Willow Biosciences Comments on Descheduling of Partner's Cannabidiol by U.S. Drug Enforcement Agency
Calgary, Alberta, December 3, 2019 – Willow Biosciences Inc.("Willow" or the "Company") (CSE: WLLW; OTCQB: CANSF), a Canadian biotechnology…
25/11/2019
Willow Biosciences Receives Conditional Approval to List on the Toronto Stock Exchange
CALGARY, November 25, 2019 – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE: WLLW; OTCQB: CANSF) announces that it has received conditional…
21/11/2019
Willow Biosciences Reports Third Quarter 2019 Results and Provides Operations Update
CALGARY, Nov. 21, 2019 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE: WLLW, OTCQB: CANSF) has released its financial and operating…
05/11/2019
Willow Biosciences To Commence Trading on The OTCQB® Venture Market
CALGARY, Alberta, November 5, 2019 — Willow Biosciences Inc. (“Willow” or the “Company”) (CSE:WLLW; OTCQB:CANSF) is pleased to announce that it has…
29/08/2019
Willow Biosciences Reports Second Quarter 2019 Results And Provides Operations Update
Calgary, Alberta – August 29, 2019 – Willow Biosciences Inc. (“Willow” or the “Company”) (CSE: WLLW) has released its financial and operating results…
04/06/2019
Willow Biosciences and Noramco Announce Joint Development of Biosynthesis Platform for Cannabidiol
New activity will add options and potential for cost savings to Noramco’s robust CBD platform in support of emerging markets CALGARY, June 4, 201…
27/05/2019
Willow Biosciences and Tuatara Capital Announce Exercise of Warrants
CALGARY, May 27, 2019 /CNW/ – Willow Biosciences Inc. (“Willow” or the “Company“) (CSE: WLLW) and Tuatara Capital Fund II, L.P. (“Tuatara“) are…
14/05/2019
Willow Biosciences Inc. Announces Share Consolidation
CALGARY, May 14, 2019 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE:WLLW) announces that it will be consolidating all of the issued…